Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications

Leukemia

Volumn 15, Issue 12, 2001, Pages 1950-1961

  Gupta, D ^a,b   Treon, S P ^a,b   Shima, Y ^a,b   Hideshima, T ^a,b   Podar, K ^a,b   Tai, Y T ^a,b   Lin, B ^a,b   Lentzsch, S ^a,b   Davies, F E ^a,b   Chauhan, D ^a,b   Schlossman, R L ^a,b   Richardson, P ^a,b   Ralph, P ^c   Wu, L ^d   Payvandi, F ^d   Muller, G ^d   Stirling, D I ^d   Anderson, K C ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c GENENTECH INC   (United States)

^d CELGENE CORPORATION   (United States)

Author keywords

Immunomodulatory drug IMiD1 CC4047; Interleukin 6; Multiple myeloma; Thalidomide; Vascular endothelial growth factor

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; BASIC FIBROBLAST GROWTH FACTOR; DEXAMETHASONE; DOXORUBICIN; DRUG ANALOG; IMMUNOMODULATING AGENT; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MITOXANTRONE; NEUTRALIZING ANTIBODY; PARAFORMALDEHYDE; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ARTICLE; BONE MARROW; CANCER CELL CULTURE; CANCER GROWTH; CANCER PATIENT; CELL ADHESION; CELL CONTACT; CELL INTERACTION; CELL TRANSFORMATION; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DONOR; DRUG RESISTANCE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN SECRETION; STROMA CELL;

EID: 0035195019     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402295     Document Type: Article

References (56)

1. Cancer statistics, 2000
2. Response pattern of purified myeloma cells to hematopoietic growth factors
3. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6
4. Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myeloma
5. Adhesion of human myeloma derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion
6. Interleukin-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade
7. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells
8. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias
9. Interleukin-6 in human multiple myeloma
10. Multiple myeloma: Increasing evidence for a multistep transformation process
11. Clinical applications of research on angiogenesis
12. Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma
13. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
14. Prognostic value of angiogenesis in operable non-small cell lung cancer
15. Tumor angiogenesis correlates with metastatic disease, n-myc amplification, and poor outcome in human neuroblastoma
16. Angiogenic factors
17. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer
18. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract
19. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue
20. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients
21. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancer
22. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphoma. An immunohistochemical and ultrastructural study
23. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia
24. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
25. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia
26. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
27. Prognostic value of bone marrow angiogenesis in multiple myeloma
28. Angiogenesis in newly diagnosed multiple myeloma: Poor prognosis with increased microvessel density (MVD) in bone marrow biopsies
29. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
30. Angiogenic factors in multiple myeloma: Higher levels in bone marrow than in peripheral blood
31. Growth factors in POEMS syndrome: Evidence for a marked increase in circulating vascular endothelial growth factor
32. Antitumor activity of thalidomide in refractory multiple myeloma
33. Thalidomide in the treatment of relapsed multiple myeloma
34. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
35. Therapy with thalidomide in refractory multiple myeloma patients - The revival of an old drug
36. Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent
37. Low-dose thalidomide in the treatment of refractory myeloma
38. Thalidomide is an inhibitor of angiogenesis
39. Thalidomide - A revival story
40. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogs that are potent inhibitors of TNF-α
41. Long term culture of human bone marrow cells
42. Transforming growth factor β1: Differential effects on multiple myeloma versus normal B cells
43. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B
44. Vascular endothelial growth factor and angiogenesis in multiple myeloma
45. Basic fibroblast growth factor serum levels in multiple myeloma patients correlate with stage of disease and lapse under therapy
46. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
47. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
48. Human vascular permeability factor: Isolation from U937 cells
49. Regulation of interleukin-6 in multiple myeloma and bone marrow stromal cells
50. Vascular endothelial growth factor (VEGF)-triggers signaling cascades mediating multiple myeloma cell growth and migration
51. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
52. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor
53. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
54. Basic fibroblast growth factor-syndecan complex at cell surface or immobilized to matrix promotes cell growth
55. Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: A multifunctional regulator of cell behavior within the tumor microenvironment
56. The cell surface proteoglycan syndecan-1 mediates fibroblast growth factor-2 binding and activity